bio-rad laboratories receives buy recommendation from ubs amid strong market presence

Bio-Rad Laboratories, Inc., a company specializing in life science research, clinical diagnostics, and analytical chemistry, has received a Buy recommendation from UBS.

The company's net sales are divided between clinical diagnostic tests and automated systems (55.8%) and reagents, equipment, and instruments for biological research (44.1%).

Bio-Rad operates 16 production sites worldwide, with five in the United States and others in Germany, France, China, Poland, the United Kingdom, Switzerland, and Singapore. The United States is the largest market for the company, accounting for 42% of net sales, followed by Europe (30.7%), Asia (21.1%), and other regions (6.2%).

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings